MedPath

Boehringer Ingelheim USA Corporation

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole

Completed
Conditions
Parkinson Disease
Interventions
First Posted Date
2014-09-11
Last Posted Date
2014-09-11
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
497
Registration Number
NCT02236728

The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and Pneumonia

Completed
Conditions
Heart Failure
Interventions
First Posted Date
2014-09-11
Last Posted Date
2014-09-11
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
26814
Registration Number
NCT02236741

Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease

Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
First Posted Date
2014-09-11
Last Posted Date
2014-09-11
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
1039
Registration Number
NCT02236715

Study to Assess the Efficacy of Ipratropium Bromide Associated With High Dose Salbutamol by Repeated Nebulisation Versus Repeat Nebulisation of Salbutamol Alone, in Acute Asthmatic Attacks in Young Children

Phase 4
Terminated
Conditions
Asthma
Interventions
Drug: Placebo
First Posted Date
2014-09-10
Last Posted Date
2014-09-10
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
3
Registration Number
NCT02235428

Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
First Posted Date
2014-09-10
Last Posted Date
2014-09-10
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
30
Registration Number
NCT02236169

A Study of Pre-hospital Treatment of Acute Myocardial Infarction Based on Diagnosis by Interpretation of Remotely Acquired ECG and Thrombolysis With Accelerated Alteplase ( Actilyse®)

Terminated
Conditions
Myocardial Infarction
Interventions
Drug: Standard therapy
First Posted Date
2014-09-10
Last Posted Date
2014-09-10
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
59
Registration Number
NCT02235389

Study to Assess the Safety of Ipratropium Bromide, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2
Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Drug: Placebo
First Posted Date
2014-09-10
Last Posted Date
2014-09-12
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
57
Registration Number
NCT02236182

A Randomised, Parallel-group, Double-blind, Double-dummy Study to Compare the Effects of Lacidipine Versus Bendrofluazide on Markers of Platelet Activation and Haemorheological Factors in Hypertensive Patients

Phase 4
Completed
Conditions
Hypertension
Interventions
Drug: Placebo
First Posted Date
2014-09-10
Last Posted Date
2014-09-10
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
26
Registration Number
NCT02235402

Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension

Completed
Conditions
Hypertension
Interventions
First Posted Date
2014-09-10
Last Posted Date
2014-09-10
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
24526
Registration Number
NCT02235415

Post-marketing Surveillance of Ventilat® in Long-term Therapy in Chronic Obstructive Pulmonary Disease

Completed
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
First Posted Date
2014-09-09
Last Posted Date
2014-09-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
595
Registration Number
NCT02233907
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy